Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin

Eid, Hussein M.; Naguib, Ibrahim A.; Alsantali, Reem I.; Alsalahat, Izzeddin; Hegazy, Amira M.

doi:10.1016/j.xphs.2021.04.020

Cited by 43 publications

(30 citation statements)

References 52 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ZP values of the NLC formulations ranged between −35.1 and −27.5 mV ( Table 1 ). The high negative values mean that the formed nanoparticles are expected to be stable based on ZP results [ 36 ]. ANOVA Type III analysis of ZP values revealed no significant impacts of GMS, OA, or poloxamer 407.…”

Section: Resultsmentioning

confidence: 99%

“…The surface charge of the particles is represented by ZP, which reflects the extent of repulsion between similarly charged particles in the dispersion, preventing particle aggregation and demonstrating the stability of the dispersion. According to the Derjaguine Landaue Verweye Overbeek (DLVO) theory, if the surface charge is higher than 30 mV (negative or positive), the system is assumed to be stable [ 36 ]. The high positive charge of BER-CTS-NLCs (36.8 mV) therefore suggests their good stability.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route

et al. 2022

Self Cite

View full text Add to dashboard Cite

This research aimed to design, optimize, and evaluate berberine-laden nanostructured lipid carriers overlaid with chitosan (BER-CTS-NLCs) for efficient brain delivery via the intranasal route. The nanostructured lipid carriers containing berberine (BER-NLCs) were formulated via hot homogenization and ultrasonication strategy and optimized for the influence of a variety of causal variables, including the amount of glycerol monostearate (solid lipid), poloxamer 407 (surfactant) concentration, and oleic acid (liquid lipid) amount, on size of the particles, entrapment, and the total drug release after 24 h. The optimal BER-NLCs formulation was then coated with chitosan. Their diameter, in vitro release, surface charge, morphology, ex vivo permeability, pH, histological, and in vivo (pharmacokinetics and brain uptake) parameters were estimated. BER-CTS-NLCs had a size of 180.9 ± 4.3 nm, sustained-release properties, positive surface charge of 36.8 mV, and augmented ex-vivo permeation via nasal mucosa. The histopathological assessment revealed that the BER-CTS-NLCs system is safe for nasal delivery. Pharmacokinetic and brain accumulation experiments showed that animals treated intranasally with BER-CTS-NLCs had substantially greater drug levels in the brain. The ratios of BER brain/blood levels at 30 min, AUCbrain/AUCblood, drug transport percentage, and drug targeting efficiency for BER-CTS-NLCs (IN) were higher compared to BER solution (IN), suggesting enhanced brain targeting. The optimized nanoparticulate system is speculated to be a successful approach for boosting the effect of BER in treating CNS diseases, such as Alzheimer’s disease, through intranasal therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In vitro release experiments were conducted using Franz diffusion cells (5 cm 2 surface area). A cellulose dialysis membrane was used to separate the donor chamber from the receptor chamber [ 41 ]. The donor chamber contained a particular volume of the optimized BER-CTS-BLS and BER solution (equivalent to 3 mg).…”

Section: Methodsmentioning

confidence: 99%

Surface-Modified Bilosomes Nanogel Bearing a Natural Plant Alkaloid for Safe Management of Rheumatoid Arthritis Inflammation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory illness affecting the joints. The characteristic of RA is gradual joint deterioration. Current RA treatment alleviates signs such as inflammation and pain and substantially slows the progression of the disease. In this study, we aimed to boost the transdermal delivery of berberine (a natural product) by encapsulating it in chitosan, surface-modified bilosomes nanogel for better management of the inflammation of RA. The chitosan-coated bilosomes loaded with berberine (BER-CTS-BLS) were formulated according to the thin-film hydration approach and optimized for various causal variables, considering the effect of lipid, sodium deoxycholate, and chitosan concentrations on the size of the particles, entrapment, and the surface charge. The optimized BER-CTS-BLS has 202.3 nm mean diameter, 83.8% entrapment, and 30.8 mV surface charge. The optimized BER-CTS-BLS exhibited a delayed-release profile in vitro and increased skin permeability ex vivo. Additionally, histological examination revealed that the formulated BLS had no irritating effects on the skin. Furthermore, the optimized BER-CTS-BLS ability to reduce inflammation was evaluated in rats with carrageenan-induced paw edema. Our results demonstrate that the group treated with topical BER-CTS-BLS gel exhibited a dramatic reduction in rat paw edema swelling percentage to reach 24.4% after 12 h, which was substantially lower than other groups. Collectively, chitosan-coated bilosomes containing berberine have emerged as a promising therapeutic approach to control RA inflammation.

show abstract

“…The entrapment of CT in CT-CS-LPs was calculated indirectly by analyzing CT in the supernatant after centrifugation and then subtracting from the quantity added during formulation. The centrifugation was established via a cooling centrifuge (SIGMA 3-30K, Germany) for 3h (14,000 rpm, 4°C) to separate the supernatant containing free CT. 28 The concentration of CT in the supernatant was estimated spectrophotometrically (Jasco V-530, Japan) at 271 nm after suitable dilution. The percentage of CT entrapment was calculated using the following equation:…”

Section: Citicoline Entrapment Efficiencymentioning

confidence: 99%

“…TEM (Jeol, Tokyo, Japan) examines the formulation at 80 kV. 28 The pH of the optimized CT-CS-LPs formulation was assessed via a calibrated pH meter (Jenway, UK).…”

Section: Analysis Of Morphology and Phmentioning

confidence: 99%

Potential Use of Tailored Citicoline Chitosan-Coated Liposomes for Effective Wound Healing in Diabetic Rat Model

Eid¹,

Ali²,

Ali³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

This study aimed to formulate citicoline-loaded chitosan-coated liposomes (CT-CS-LPs) for topical administration and evaluated for wound healing in a diabetic animal model. Methods: CT-LPs were formulated via a thin-film hydration approach and coated with chitosan (CS). Box-Behnken statistical design investigated the effects of lipid amount, chitosan concentration, and cholesterol amount on vesicle diameter, surface charge, and entrapment efficiency. The potential of the optimized CT-CS-LPs gel for wound healing was further evaluated in streptozocin-induced diabetic rats. The different healing stages were evaluated by several techniques, including general and special staining techniques, in addition to antibody immunohistochemistry. Results:The optimized CT-CS-LPs obtained had a mean size of 211.6 nm, a 50.7% entrapment efficiency, and a positive surface charge of 32.1 mV. In addition, the optimized CT-CS-LPs exhibited in vitro sustained release behavior. The in vivo experiments revealed that treatment with the optimized CT-CS-LPs boosts the healing process of the skin wound in diabetic rats by reducing inflammation, accelerating re-epithelization, angiogenesis, fibroblast proliferation, and connective tissue remodeling, leading to rapid wound closure. Conclusion: Chitosan-coated liposomes containing citicoline have emerged as a potential approach for promoting the healing process in diabetic rats. However, the therapeutic effectiveness of the suggested approach in diabetic patients needs to be investigated.

show abstract

Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin

Cited by 43 publications

References 52 publications

Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route

Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route

Surface-Modified Bilosomes Nanogel Bearing a Natural Plant Alkaloid for Safe Management of Rheumatoid Arthritis Inflammation

Potential Use of Tailored Citicoline Chitosan-Coated Liposomes for Effective Wound Healing in Diabetic Rat Model

Contact Info

Product

Resources

About